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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S476from the knee joint cavity, in agreement with the previously observed
hypocalcaemic effect after i.a. injection.
The efﬁcacy of the HA-sCT treatment was tested in a rabbit OA model,
where a chondroprotective effect of the highest dose tested was proven
by macro- and microscopic assessments and histological ﬁndings. The
cartilage surfaces of the weight-bearing parts, such as the medial tibial
plateau and the lateral and medial femoral condyle, were evaluated and
graded for degradation severity
The average scores on the macroscopic assessment of sCT or HA-sCT
treated group indicated a signiﬁcant reduction in cartilage damage in
comparison to controls.
PAS staining of nuclei, indicating the maintenance of chondrocyte
number, and Alcian blue staining of proteoglycan, indicating the matrix
integrity of the cartilage, were signiﬁcantly positive in the majority of
the HA-sCT treated groups.
Conclusions: The in vivo PK and efﬁcacy/safety proﬁles of sCT and HA-
sCT were examined in this study in view of a potential application in the
treatment of OA. Although the i.a. injection of the different sCT-based
formulations showed to be comparably chondroprotective in a
mechanical model of OA in vivo, the HA-peptide conjugate has the
advantage of a sustained action and of a decrease in systemic exposure
to sCT with consequent potential safety concerns. The promising results
encourage further development and investigation on this therapeutic
approach for OA.
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HYALURONIC ACID ALKYL DERIVATIVE (HYADD4) SHOWING
INHIBITORY ACTIVITY ON HYALURONIDASES
M. Pavan, D. Galesso, C. Guarise. Fidia Farmaceutici spa, Abano Terme,
Italy
Purpose: Hyaluronic Acid (HA) homeostasis in the knee is based on a
ﬁne balance between synthesis and degradation; in pathological con-
ditions, Hyaluronidases (speciﬁcally Hyal-2) play a key role in HA
catabolism. The reduction of endogenous HA Molecular Weight (MW)
and concentration in Synovial Fluid (SF) is one of the molecular signals
of Osteoarthritis (OA) progression. Viscosupplementation is an intra-
articular pharmacological therapy based on mechanical restoration of
joint performance; to date, no polymer used in viscosupplementation is
known to have an inhibitory action on Hyaluronidases. We present here
a novel series of HA alkyl-amide derivatives (HYADD) which, besides
good rheological performances, show inhibition of Hyal-2, suggesting a
possible biological effect in SF degradation.
Methods: Several unmodiﬁed and chemically modiﬁed polymers
actually used in viscosupplementation therapy were compared for their
inhibitory effect on the hyaluronidase enzymatic action towards HA.
Therefore, in presence of these polymers, HA (2000 kDa) was incubated
at 37C as a substrate for Bovine Testis Hyaluronidase (BTH) and the
resulting MW was determined by means of SEC-TDA Viscotek. In order
to avoid the physical entrapment effect, the experiment was repeated
after depolymerization of the testmaterials by heating at 105C for 24 h,
before incubation with HA. Since only the HA hexadecylamide
(HYADD4) was able to preserve the initial HA MW, a series of HA
amide derivatives with different alkyl/aryl side chains were tested in
terms of Hyaluronidase inhibition, with the aim of verifying the inﬂu-
ence of their structure on this activity. C8-, C12-, C15-, C16-, C18- and
benzyl- amide of HA were then synthesized and their IC50 versus BTH
was obtained using HA as substrate andmeasuring its MWat increasing
inhibitor concentration. HYADD-C16 (HYADD4) was selected as lead
compound on the basis of its good balance between potency and
solubility.
Finally, the activity of HYADD4 (formulated at 8 mg/ml in PBS pH 7)
was validated ex-vivo in human SFs collected by arthrocentesis from OA
patients (n ¼ 3); the SFs were not centrifuged in order to avoid the loss
of Hyal-2, located on the cell surface. HYADD4 was incubated at 37C
in the SFs (unmodiﬁed HA was used as control); after 24 h CuCl2 100
mm was added, which allowed the precipitation of proteins and the
analysis of the endogenous HA molecular weight.
Results: The MW of HA incubated with BTH in presence of 4 out of 5
polysaccharides tested dropped in just 60 min from 2000 kDa to about
400 kDa; in presence of HYADD4, even after 24 h, HA preserved its
initial MW. The results were conﬁrmed after depolymerization of the
polymer: HYADD4 was still able to completely inhibit BTH, thus pre-
venting HA cleavage.
The comparison of IC50 of the different HYADD
 derivatives highlighteda strong correlation between the alkyl chain length and the ability to
inhibit BTH. Benzyl-, C8- and C-12 derivatives showed no interaction
with the enzyme, while C15-, C16- and C18- derivatives proved to be
stronger inhibitors (IC50 of 276.5  4.7, 166.5  2.6 and 149.7  2.1 mM,
respectively). HYADD4 was therefore selected as lead compound
because of its best compromise between solubility and potency.
The ex-vivo test on OA SFs demonstrated that HYADD4 at 425 mM is
able to slow down the degradation of endogenous HA by Hyal-2, which
is markedly faster in the control test where exogenous unmodiﬁed HA
was used (n ¼ 3, P < 0.001).
Conclusions: In this study we found that some alkyl-amide derivatives
of HA (HYADD), compared to other polysaccharides used in the pro-
duction of viscosupplements, possess the unique ability to inhibit
Hyaluronidases. This property was demonstrated in vitro through the
measurement of IC50 against BTH and then conﬁrmed ex-vivo in OA SFs
for the selected lead compound, HYADD4, , which was shown to
protect endogenous HA from Hyal-2 degradation. The intra-articular
administration of the biopolymer has also the advantage of overcoming
easily the possible issues of systemic distribution and chronic toxicity,
that are common for the small molecule inhibitors.
870
SELECTIVE INHIBITION OF MATRIX METALLOPROTEASE-13 BY
HYALURONIC ACID ALKYLAMIDE DERIVATIVES FOR THE INTRA-
ARTICULAR TREATMENT OF OSTEOARTHRITIS
C. Guarise, M. Pavan, D. Galesso. Fidia Farmaceutici s.p.A., Abano Terme
(PD), Italy
Purpose: In the pathophysiology of osteoarthritis (OA) several media-
tors are involved, however the attempts to develop a drug acting on
speciﬁc targets involved in OA progression (e.g. Matrix Metal-
loproteases: MMPs) failed at various stages due to unfavourable phar-
macokinetics or chronic toxicity. On the other hand Hyaluronic Acid
(HA) is widely used as an intra-articular therapy for OA thanks to its
capacity of restoring viscoelasticity and lubrication in degraded syno-
vial ﬂuid and to its beneﬁcial effects on inﬂammation and cartilage
metabolism.
We describe here the selection of a HA alkylamide derivative
(HYADD4) with inhibitory activity in the micromolar range vsMMP13,
for the intra-articular treatment of OA patients.
Methods: Chlostridium histolyticum Collagenase (ChC) was used as
model of MMP. A number of selected glycosaminoglycans currently
used in viscosupplements were compared for their inhibitory effect on
ChC enzymatic activity: Chondroitin Sulfate (CS), unmodiﬁed HA, HA
cross-linked and HA amidated with hexadecylamine, all formulated at 8
mg/ml in PBS pH 7, were incubated in presence of ChC at 37C and
samples withdrawn at different timepoints were tested in a ChC activity
assay. In order to abolish the effect of physical entrapment of the
enzyme, the test was repeated after depolymerization of the materials
by heating at 105C for 24 h before incubation with ChC.
For the screening of the modiﬁed HAs: six amide derivatives of HAwere
synthesized by alkylation at the carboxylic group of the D-Glucuronic
acid unit with a series of linear alkyl chains C8, C12, C15, C16, C18 and a
benzyl group, at the same amidation degree. The inhibition constant
(Ki) of the depolymerized HA amide derivatives, versus ChC was
measured by steady-state kinetics experiments at several inhibitor
concentration.
The compound selected as the best ChC inhibitor (HYADD-C16 or
HYADD4) was then tested in vitro vs the catalytical subunits of 10
human MMPs using a MMP Inhibitor Proﬁling Kit. The selective inhib-
itory activity of HYADD4 vsMMP13 observed in the screening test was
ﬁnally validated on the human enzyme in an ex-vivo experiment with
human inﬂamed synovial ﬂuid (SF), collected by arthrocentesis and
analyzed by means of a human MMP13 assay kit.
Results: In the ﬁrst screening test the cross-linked HA and HA hex-
adecylamide, but not CS and high MW HA, showed a relevant decrease
of the ChC activity (probe metalloprotease). In order to rule out the
hypothesis that the inhibitionwas due to simple physical entrapment of
the enzyme in the test materials, the experiment was repeated after
depolymerization of the polysaccharides: in these conditions ChC
activity was almost completely recovered in the case of cross-linked
HAs, while depolymerized HA hexadecylamide (HYADD4) caused a
further loss of enzyme activity, as a proof of speciﬁc inhibition.
Since the HA alkylamide showed this unique property, in the second
part of the work six different amide derivatives of HA, synthesized with
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tested for the inhibitory activity against ChC. The inhibitor potency
showed to be directly correlated to the length of the alkyl chain. The C16
alkyl amide derivative HYADD4 was identiﬁed as lead compound (Ki¼
6.21.6 mM), on the basis of the best compromise between potency and
solubility.
With the aim of assessing the speciﬁcity of the effect, HYADD4 was
then screened vs 10 different human MMP catalytic subunits, showing
higher selectivity for MMP8 and MMP13. The Ki against human MMP13
was found to be in the micromolar range (61.7  7.0 mM).
Finally, since MMP13, unlike MMP8, is involved in OA progression, an ex
vivo study was performed by incubating HYADD4 in SF from patients
with inﬂammatory arthritis: the Ki value obtained (106.1  9.2 mM) was
comparable to that observed in vitro, thus validating the inhibitory
activity against MMP13.
Conclusions: These data suggest that the extremely hydrophobic side
chain of HYADD4, whose water solubility is boosted by the HA back-
bone, is pivotal in the mechanism of MMP competitive inhibition.
The polymer structure suggests that the alkyl side chain could easily
and selectively dock the hydrophobic S1’ pocket in the MMP catalytic
domain.
The hexadecyl derivative shows the best performance against MMP13
and MMP8, as conﬁrmed also in an ex-vivo experiment in SF vs human
MMP13. Furthermore, the intra-articular administration of the alkyl-
modiﬁed HA as a treatment for OA, thanks to its site-selectivity and
solubility, can overcome the common issues of the small molecule MMP
inhibitors, such as systemic distribution and toxicity.
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EVALUATION OF A POLYACRYLAMIDE HYDROGEL IN THE
TREATMENT OF INDUCED OSTEOARTHRITIS IN A GOAT MODEL: A
RANDOMIZED CONTROLLED PILOT STUDY
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Taastrup, Denmark; zDept. of Vet. Disease Biology - Univ. of
Copenhagen, Copenhagen, Denmark; xDept. for Clinical Vet. & Animal
Sci. - Univ. of Copenhagen, Copenhagen, Denmark; kDairy Technology-
Univ. of Copenhagen, Copenhagen, Denmark; {RigsHosp.et - Univ. of
Copenhagen, Copenhagen, Denmark
Purpose: Polyacrylamide hydrogel (PAAG) is an inert, non-degradable,
non-immunogenic polymer gel with high viscoelasticity consisting of
97.5% sterile water and 2.5% cross-linked polyacrylamide. Its bio-
compatibility in soft tissues has been demonstrated. PAAG has recently
been tested for the treatment of osteoarthritis (OA) in horses with
highly encouraging results; however no standardized experimental
studies have been done to explore its efﬁcacy. The purpose of this study
was to evaluate PAAG in the treatment of induced OA in a goat model.
Methods: A randomized controlled study was conducted involving
goats with induced OA on the left stiﬂe (knee) joint. OA was surgically
induced by the transection of the medial collateral ligament, the
bisection of the medial meniscus at its midpoint and partial-thickness
incisions of the cartilage of the medial tibial plateau. Goats were
allowed free exercise, and 3 months after surgery they were randomly
divided into 2 groups: group 1 (n¼ 4): PAAG and group 2 (n¼ 2): saline
solution (control). Treatments were injected intraarticularly. MRI of the
left knee had been performed prior to surgery, at the time of injection (3
months) and 4, 5 and 7 months post-surgery. T1, T2/PD and Stir
weighted MRI images were used to assess OA. All goats were clinically
evaluated on ground and on treadmill and videotaped for evaluation by
3 blinded observers. Haematology, biochemistry and acute phase pro-
teins were also assessed. The goats were euthanized 7 months after
surgery, and gross pathology and histopathology, including immuno-
histochemistry for nerve endings (n ¼ 3 joints), were performed on
both femorotibial joints. The hardness of the joint capsule was meas-
ured in both groups using Instron  5564 testing system (HIS Global-
Spec, MA, USA).
Results: At the end of the study, 75 % of the goats treated with PAAG
were clinically sound, and 25 % of them had not improved, whereas the
2 control goats were still lame. In both groups, the values of haema-
tology, biochemistry, or acute phase proteins werewithin normal range.
MRI showed that in group one, 3 out of 4 goats had a decrease followed
by a stabilization of OA lesions, while 1 goat had a mild progression of
the OA lesions. In group 2, both goats had a mild or marked increase ofOA lesions. Gross pathology inspection in group 1 demonstrated that all
the operated knees showed typical signs of OA. The inner synovial lining
was thickened, and the cartilage surface was uneven in all cases. The gel
was seen in various amounts adhering to the inner side of the joint
capsule in all the goats of group 1. Gross inspection of both goats in
group 2 also showed cartilage lesions and synovial thickening, but the
histopathological investigations revealed this to be more prominent in
group 1 than in group 2. It comprised angiogenesis, collagen and
synovial cell increase, and in the injected goats, also the gel. The nerve
endings were normal looking and in normal numbers. The investigation
of the joint capsule hardness showed that in the treated knee of the
goats of group 1, the medial side (injected with PAAG) was always less
hard than the lateral side.
Conclusions: This study demonstrated the efﬁcacy of a novel treat-
ment of OA, with 75 % of the goats treated with PAAG being clinically
sound. Treatment with PAAG did not have any inﬂuence on haema-
tology, biochemistry, or acute phase proteins. It induced a moderate
synovial hyperplasia of the inner side of the capsule with trapped
(integrated) gel, increased angiogenesis and collagen production. Pre-
liminary pathology and joint capsule hardness data suggest that PAAG
might act mainly on the joint soft tissue and especially the synovial
membrane. PAAG might have 2 effects on OA joints: 1- Joint capsule
was less hard on the treated (medial) than on the non-treated (lateral)
side and had a lower hardness when compared to group 2. OA joints
typically show joint stiffness - a major source of pain in OA. By
decreasing the joint capsule hardness, and thus joint stiffness, PAAG
might relieve the pain in the OA joint (“disease-modifying” effect). 2-
MRI and pathology investigations have revealed a stabilization of OA
lesions in the goats of group 1, which might be explained by the
mechanical effect through the high viscosupplementation provided by
PAAG that was still present in the joint cavity (“disease-stabilizing”
effect). No adverse reaction was seen following intraarticular injection
of PAAG. More investigations are needed to fully understand the
mechanism of action of PAAG in improving clinical signs and in sta-
bilizing OA. This pilot study may be used as a basis for further studies
using larger animal numbers.
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EVALUATION OF NANOSTRUCTURED VECTORS FOR THE TREATMENT
OF OSTEOARTICULAR PATHOLOGIES
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Purpose: One of the major problems in treatment of osteoarticular
diseases is to reach cells inside the matrix to provide drug. Indeed,
cartilage is an avascular tissue with a few cells feed by diffusion through
a dense protein network (collagens, glycosaminoglycans). In this work
we have designed polymeric nanoparticles (NPs) of poly (D, L-lactic/glycolic acid)(PLGA) synthesized by a double emulsion method, which
are biocompatible, biodegradable and can encapsulate water-soluble
agents. Our NPs are labelled with BSA coupled to a ﬂuorescent dye
(Cyanine-3) to follow them by epiﬂuorescent microscopy. As articular
